Dr. Brentjens on CD19-Targeted T Cells in CLL and ALL
2 Visualizzazioni
• 07/14/23
0
0
Incorporare
administrator
Iscritti
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-Targeted T Cells.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti